Description
The 927 monoclonal antibody specifically recognizes CD317 which is also known as Bone marrow stromal antigen 2 (BST2) or Plasmacytoid Dendritic Cell Ag-1 (PDCA-1). CD317 (BST2) is a type II transmembrane glycoprotein that is encoded by Bst2. It is highly expressed on naïve plasmacytoid dendritic cells (pDC) which comprise very small populations within lymphoid and nonlymphoid tissues. pDC are characteristically early responders to viruses through Toll-like receptors (TLR), TLR7 and TLR9. Activated pDC can produce large amounts of proinflammatory cytokines including type I interferons, Interferon-alpha (IFN-α) and Interferon-beta (IFN-β), and are also known as Type I IFN producing cells (IPC). CD317 (BST2) expression can be upregulated on a variety of other cell types following stimulation with type I IFNs and IFN gamma including T cells, B cells, plasma cells, NK cells, CD8+ and CD8- dendritic cells, and cell lines. CD317 (BST2) may play a role in sorting proteins, eg, cytokines, from the Golgi apparatus and the plasma membrane.
Bead-based compensation or unmixing controls, such as BD® CompBeads or BD™ SpectraComp™, can be used as surrogates to assess fluorescence spillover when bound to fluorochrome-conjugated antibodies. Although these beads have spectral properties similar to cells, variations in spectral emission may occur, resulting in differing spillover values compared to biological controls. Therefore, it is considered best practice to compare the spillover obtained from cells and bead-based controls when using BD® CompBeads or BD™ SpectraComp™ for the first time, to ensure they are appropriate for the intended application.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
2. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
3. For U.S. patents that may apply, see bd.com/patents.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
6. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
7. When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
8. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
9. An isotype control should be used at the same concentration as the antibody of interest.
10. Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
11. Alexa Fluor™ is a trademark of Life Technologies Corporation.
Specifications

General

BrandBD OptiBuild™
Alternative NameBst2; BST-2; PDCA-1; PDCA1; Tetherin; DAMP-1; GREG
ReactivityMouse (Tested in Development)
IsotypeRat IgG2b, κ
ImmunogenMouse bone marrow-derived type I IFN-producing cella (IPC)
ApplicationFlow cytometry (Qualified)
Concentration0.2 mg/ml
Storage BufferAqueous buffered solution containing ≤0.09% sodium azide.
Regulatory StatusRUO